This is an innovative molecule with a unique mechanism of action for the treatment of androgen-dependent conditions, such as alopecia and acne.

In pre-clinical studies, it has shown promising activity in various models of acne, alopecia and hirsutism. The product has good systemic and dermal tolerance.

In human clinical pharmacology, there was no systemic anti-androgenic activity and again good general and dermal tolerance.

The molecule has completed several Phase I studies and a Proof of Concept Phase II study for alopecia.

It has demonstrated similar efficacy after 6 months treatment as that observed with current oral therapy for alopecia after twelve months, based on the increase in net hair count. Again, no systemic anti-androgenic effect was observed (n=90).

This product is available for licensing.